Indivior Share News (INDV)

LONDON BROKER RATINGS: Berenberg lowers Spectris; RBC cuts Direct Line

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

LONDON MARKET CLOSE: Records for FTSE and CAC but US PPI hits New York

(Alliance News) - Blue-chip benchmarks in London and Paris hit record highs on Thursday, with the FTSE 100 managing to cling to its daily gain, despite some weakness following US producer price data.

CORRECT: LONDON MARKET MIDDAY: FTSE 100 stays above 8,000

(Correcting the GBPUSD quote).

LONDON MARKET MIDDAY: FTSE 100 stays above 8,000 as Centrica jumps

(Alliance News) - Stock prices in London were higher at midday on Thursday, with London's flagship index still trading above the 8,000 mark on the back of strong performances from Centrica and Relx.

CORRECT: Indivior shares down on swing to annual loss

(Correcting litigation provision is against 2022 results.)

TOP NEWS: Indivior shares down on swing to annual loss

(Alliance News) - Indivior PLC on Thursday reported a swing to a full-year loss due to a provision for litigation, despite net revenue jumping by 14% due to growth in its Sublocade injection.

LONDON MARKET OPEN: FTSE 100 tops 8,000; Centrica is star performer

(Alliance News) - Stock prices in London opened higher on Thursday, with London's blue-chip index pushing past the 8,000 mark once again, a day after it first broke the barrier.

LONDON BRIEFING: Centrica, Indivior swing to loss; StanChart bullish

(Alliance News) - Stocks in London were set to open higher on Thursday, with the FTSE 100 called to push past the 8,000 mark again at the open.

Indivior shares tumble as group sets aside $290m for US litigation

(Sharecast News) - Shares in pharmaceuticals business Indivior tumbled early on Thursday after the group revealed it had put aside $290.0m for ongoing litigation in the States.

UK earnings, trading statements calendar - next 7 days

Indivior announces expiry of waiting period for Opiant purchase

(Alliance News) - Indivior PLC has announced on Monday the expiration of the waiting period relating to its USD145 million purchase of Opiant Pharmaceuticals Inc.

LONDON MARKET CLOSE: Pharma stocks fail to lift FTSE 100 in the green

(Alliance News) - Stocks in London closed in the red on Wednesday, despite a strong performance from pharmaceutical stocks, as investors digested a raft of economic data from both China and Europe.

Indivior targets Nasdaq listing for spring 2023 as hails Sublocade

(Alliance News) - Indivior PLC on Wednesday said it aims to list on the Nasdaq in spring 2023 as it expects its injection Sublocade to reach peak annual net revenue of over USD1.5 billion.

Indivior raises guidance for peak net revenue potential of Sublocade asset

(Sharecast News) - Pharmaceuticals business Indivior upgraded guidance for the peak annual net revenue potential of its Sublocade asset on Wednesday ahead of its Capital Markets Day event in New York City.

Indivior buys Opiant creating "comprehensive" treatment platform

(Alliance News) - Indivior PLC on Monday announced the acquisition of Opiant Pharmaceuticals Inc for around USD145 million.